COCRYSTAL PHARMA, INC. Selling and Marketing Expense
COCRYSTAL PHARMA, INC. (COCP) reported Selling and Marketing Expense of $86.77 thousand for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2013-11-18
- COCRYSTAL PHARMA, INC. selling and marketing expense for the quarter ending 2013-09-30 was $86.77K, a 47.00% increase year-over-year.
- COCRYSTAL PHARMA, INC. selling and marketing expense for the quarter ending 2013-06-30 was $166.34K, a 31.54% decline year-over-year.
- COCRYSTAL PHARMA, INC. selling and marketing expense for the quarter ending 2013-03-31 was $175.26K, a 20.90% decline year-over-year.
- COCRYSTAL PHARMA, INC. selling and marketing expense for the quarter ending 2012-12-31 was $367.49K, a 103.70% increase year-over-year.
- COCRYSTAL PHARMA, INC. selling and marketing expense for fiscal 2012 was $774.78K, a 14.22% increase from fiscal 2011.
- COCRYSTAL PHARMA, INC. selling and marketing expense for fiscal 2011 was $678.34K.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month |
|---|---|---|---|---|---|---|
| 2013-09-30 | $86.77K 10-Q · filed 2013-11-18 | $253.11K derived: sum of 2 quarters · filed 2013-11-18 | $386.99K 10-Q · filed 2013-11-18 | $795.86K derived: sum of 4 quarters · filed 2013-11-18 | ||
| 2013-06-30 | $166.34K 10-Q · filed 2013-08-15 | $341.60K 10-Q · filed 2013-08-15 | $709.09K derived: sum of 3 quarters · filed 2013-08-15 | $768.12K derived: sum of 4 quarters · filed 2013-11-18 | ||
| 2013-03-31 | $175.26K 10-Q · filed 2013-05-10 | $542.75K derived: sum of 2 quarters · filed 2013-05-10 | $601.78K derived: sum of 3 quarters · filed 2013-11-18 | $844.76K derived: sum of 4 quarters · filed 2013-11-18 | ||
| 2012-12-31 | $367.49K derived: 10-K 12 month − 10-Q 9 month · filed 2013-04-01 | $426.52K derived: sum of 2 quarters · filed 2013-11-18 | $669.50K derived: sum of 3 quarters · filed 2013-11-18 | $774.78K 10-K · filed 2013-04-01 | ||
| 2012-09-30 | $59.03K 10-Q · filed 2013-11-18 | $131.09K 10-Q · filed 2012-11-14 | $302.00K derived: sum of 2 quarters · filed 2013-11-18 | $407.28K 10-Q · filed 2013-11-18 | $595.62K 10-Q · filed 2012-11-14 | $703.97K derived: sum of 4 quarters · filed 2013-11-18 |
| 2012-06-30 | $242.98K 10-Q · filed 2013-08-15 | $464.54K 10-Q · filed 2013-08-15 | $644.94K derived: sum of 3 quarters · filed 2013-08-15 | $857.73K derived: sum of 4 quarters · filed 2013-08-15 | ||
| 2012-03-31 | $221.56K 10-Q · filed 2013-05-10 | $401.97K derived: sum of 2 quarters · filed 2013-05-10 | $614.76K derived: sum of 3 quarters · filed 2013-05-10 | $761.82K derived: sum of 4 quarters · filed 2013-05-10 | ||
| 2011-12-31 | $180.41K derived: 10-K 12 month − 10-Q 9 month · filed 2013-04-01 | $393.20K derived: sum of 2 quarters · filed 2013-04-01 | $540.25K derived: sum of 3 quarters · filed 2013-04-01 | $678.34K 10-K · filed 2013-04-01 | ||
| 2011-09-30 | $212.79K 10-Q · filed 2012-11-14 | $359.85K derived: sum of 2 quarters · filed 2012-11-14 | $497.94K 10-Q · filed 2012-11-14 | |||
| 2011-06-30 | $147.06K 10-Q/A · filed 2012-09-28 | $285.15K 10-Q/A · filed 2012-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |